Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)